kabutan

Oncolys BioPharma submits IND application for new indication of OBP-301

Wed Jun 3, 2026 3:59 pm JST Catalyst

Oncolys BioPharma Inc. <4588> announced after the close on June 3 that it has submitted an Investigational New Drug (IND) application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for a Phase 1b/2a clinical trial of its oncolytic virus OBP-301, targeting new indications of lower rectal and anal cancer. The study will evaluate the efficacy and safety of OBP-301 when combined with preoperative chemoradiotherapy. Oncolys plans to begin patient dosing within the fiscal year ending December 2026.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles